Säilyykö myönteinen elämänasenne vanhuudessa?

Tutkimuksen tarkoituksena oli arvioida 70-vuotiaiden, kotona asuvien ikäihmisten koettua elämänasennetta sekä seurata sen pysyvyyttä ja siinä tapahtuneita muutoksia 20 vuoden seuranta-aikana. Lähtötutkimus toteutettiin postikyselynä vuonna 1991, jolloin tutkimuskohteena olivat kaikki vuonna 1920 syntyneet (N=1530) kotona asuvat turkulaiset. Heidät tutkittiin uudelleen vuonna 2001 (n=656), 2006 (n=304) and 2011 (n=156). Elämänasennetta arvioitiin kysymyksillä elämään tyytyväisyydestä, tarpeellisuuden tunteesta, tulevaisuuden suunnitelmista, elämänhalusta, masentuneisuudesta ja yksinäisyydestä. Kysymyksistä muodostettiin summamuuttuja, jonka arvo 1 edustaa positiivista elämänasennetta ja arvo 0 negatiivista elämänasennetta. Lähtötilanteessa vastaajilla oli varsin myönteinen elämänasenne (summamuuttujan arvo 0.83). Heillä oli elämänhalua ja he olivat elämäänsä tyytyväisiä. Seuranta osoitti, että kotona asuvien ikäihmisten elämänasenne heikkeni tilastollisesti merkitsevästi ikävuosien 70 ja 80 välillä (0.83:sta 0.75:een), kun taas ikävuosien 80, 85 ja 90 välillä muutosta ei enää tapahtunut

Ambulatory Monitoring Uncorrected for Placebo Overestimates Long-term Antihypertensive Action

Abstract 'This study compares blood pressure (BP) changes during active antihypertensive treatment and placebo as assessed by conventional and anlbulatory BP measurement. Older patients (260 years, n=337) with isolated systolic hypertension by conventional sphygrnomanometry at the clinic were rando~nized to placebo or active treatment consisting of nitrendipine (10 to 40 mgid), with the possil~le addition oF enalapril (5 10 20 mgid) ;~nd/or hydrochlorothiazide (12.5 Lo 25 mg/d). At baseline, clinic systolic/diastolic BP averaged 175186 mm Hg and 24-hour and daytimc ;~mbulatory BPs averaged 148180 and 154185 mm Hg, respectively. After 13 months (median) of active treatment, clinic BP had dropped by 22.717.0 mm Hg and 24-hour and daytime BPs by 10.514.5 and 9.714.3 mm Hg, respectively (P<.001 for all). However, clinic (9.811.6 mm Hg), 24-hour (2.11 1.1 nini Hg), and daytime (2.911.0 mm Hg) BPs decreased also during placebo (P<.05, except for daytime diastolic BP); these decreases represented 43%/23%, 20%/24%, and 30%/23% of the corresponding BP fall during active treatment. After subtraction of placebo effects, the net BP reductions during active treatment averaged only 12. 915.4, 8.313.4, and 6.813.2 mm Hg for clinic, 24-hour, and daytime BPs, respectively. The effect of active treatment was also subject to diurnal variation (R.05). Changes during placebo in hourly systolic and diastolic BP means amounled to (median) 21% (range, -1% to 42%) and 25% (-3% to 72%), respectively, of the corresponding changes during active treatment. In conclusion, expressed in millimeters of mercury, the effect of antihypertensive treatment on BP is larger with conventional than with ambulatory measurement. Regardless of whether BP is measured by conventional sphygmomanometry or ambulatory monitoring, a substantial proportion of the long-tern~ BP changes observed during active treatrnent may be attributed to placebo effects. Thus, ambulatory monitoring uncorrected for placebo or control observations, like conventional sphygmomanometry, overestimates BP responses in clinical trials of long duration. (Hypertension. lYY6;27[part 1]:414-420.) Key IYords blood pressure monitoring, ambulatory antihypertensive therapy clinical trials blood pressure monitoring placebo T he SYST-EUR Trial is a double-blind, placebocontrolled outcome trial in older patients with isolated systolic hypertension that the European Working Party on High Blood Pressure in the Elderly is currently conducting in Western and Eastern Europe and in 1srael.l Presently, the 3000 patients originally planned lor have been randomized. In accordance with current clinical practice,2 only conventional sphygmomanometric BP readings by an auscultating observer determine a patient's eligibility for randomization and guide the stepwise adjustments of treatment during the double-blind phase of the trial. ' In addition to conventional sphygmomanometry, arnbulatory BP monitoring is increasingly used in clinical trials to evaluate the magnitude and duration of the BP-lowering action of antihypertensive agents. SYST-EUR centers can opt to monitor their patients in an attempt to evaluate whether the ambulatory BP, over ancl above the clinic BP, is helplul in predicting cardiovascular events.' This article builds on the data collected so Tar in the SYST-EUR Trial1 and contrasts the effects Received August 25, 1995; first decision September 18, 1995; revision accepted October 31, 1995. Correspondence to Jan A. Staessen, MD, PhD, Klinisch Labo-~;ltol.iuni Ilypertensie, Inwendige Geneeskunde-Cardiologie, U Z Gaslhuisberg, Herestraat 49, Belgiu~n. 0 L996 American Heart Association, Inc. of antihypertensive treatment and placebo as assessed by conventional sphygmomanometry and ambulatory monitoring. 11 extends the findings o l a previous article that was limited to the placebo arm of the triaL4 Methods Study Design 'The protocol of the SYST-EUR Trial has been published elsewhere.' It was approved by the Ethics Committee of the Faculty of Medicine at the University of Leuven as well as by the institutional review committees of all participating centers. Patients were eligible (I) if they were at least 60 years old; (2) if, on a placebo during the run-in phase, their sitting SBP ranged from 160 to 219 mm Hg with a DBP below 95 mm Hg; (3) if their standing SBP was 140 mm Hg or higher; and (4) if, after having been informed, they voluntarily consented to be enrolled. The BP criteria for entry rested on the averages of six silting and six standing readings, ie, two in each position at three baseline visits I month apart. Eligil~le patients were stratifed by sex and the presence versus absence of cardiovascular complications and were randomized to double-blind treatment with active medication or placebo. Aclive treatment consisted of nitrendipine BP and Other Measurements SYST-EUR centers opting to take part in ambulatory rnonitoring were asked to perform recordings at baseline, at 6 and 12 months, and annually thereafter? Validated5.Wonitors were programmed to obtain measurements at intervals not greater than 30 minutes. The conventional BP corresponding to each ambulatory recording was the average of the two readings with patients in the sitting position obtained at the nearest clinic visit. The patients were interviewed at baseline and follow-up concerliing their smoking habits, habitual alcohol intake, and activities of daily l i~i n g .~,~ In addition, the serum activity of yglulanlyllranspeptidase was determined as an index of alcohol intake." Analysis of the Diurnal BP Profile If the ambulatory recordings were longer than 24 hours, only the first 24 hours was used for analysis. Recordiligs were excluded whenever the available readings constituted less than 80% of those program~netl or covered less than 22 consecutive hours. I'he editing criterial".ll considered for tlelelion of readings from the recordings were (1) SBP<DBP, (2) SBP >240 or <40 mm Hg, (3) DBP >I40 or <40 mm Hg, (4) pulse rate >l50 or <40 beats per minute, and (5) pulse pressure <10% of SBP. The 24-hour, daytime, and nighltime pressures and hourly BP means were weighted for the time between consecutive readings. l 2 Daytime was from I0 AM to 8 PM and nighttime from mitlnight to 6 AM. These dcfnitions of daytime ancl nighttime have been used in previous s t~d i e s~~'~~~ and exclude the transition periods in the morning and evening during which BP changes rapidly. The awake and sleeping periods were determined from diary cards kept by the patients on recording days.7 Statistical Analysis Database management and statistical analyses were performed with the SAS software (SAS Institute Inc). Statistical methods included Student's t test and linear regression analysis. Diurnal BP profiles, drawn from hourly BP means, were contrasted by repeated measures ANOVA,I4 considering as main effects treatment allocation (active versus placebo) and time of day. For establishment of whether the antihypertensive action was steady over 24 hours, the model also tested for a treatment-time interaction. The net treatment effect, sometimes referred to as the double delta of BP," was calculated by subtracting the mean change from baseline during placebo from the corresponding change during active treatment. The 95% confidence limits about the net treatment effect showed the times during the day when the BP reduction was significant. The reproducibility of duplicate measurements was studied by the Bland and Altman technique.lh For co~nparison of the reproducibility of various BP measurements, the repeatability coefficients were expressed as a percentage of nearly maximal variation, ie. the interval encompassing four times the S D of the averaged tluplicate measurements. Results Data Available for Analysis On May 15, 1995, 407 patients had their ambulatory BP recorded during the run-in phase of the trial and at least once after randomization. In 174 of these patients, duplicate recordings had been obtained at baseline. After patients with incomplete recordings were excluded, these numbers were 337 and 118, respectively. The 792 ambulatory recordings included in the present analysis comprised a total of 51 960 single BP readings, of which only 1.5% complied with at least one of the criteria considered for editing. In 501 recordings (63%), no single reading met the editing criteria. Because editing did not influence the results, only analyses based on unedited recordings are presented. Patient Characteristics at Randomization The patients allocated to placebo (n=169) and active treatment (n= 168) had the same characteristics at randomization. They comprised 142 men and 195 women. Cardiovascular complications were present in 94 patients. Of the 337 patients, 167 had been treated during the 6 months before they were considered for entry into the trial, 30 with diuretics, 19 with P-blockers, 21 with converting enzyme inhibitors, 33 with calcium entry blockers, and 64 with various other drugs or with a combination of several antihypertensive agents. Previous antihypertensive treatment was usually discontinued l month before the first run-in visit during placebo. The median time interval between the latter visit and randomization was 76 days (range, 36 to 300) in the previously treated patients and 70 days (range, 20 to 300) in the other patients. In all 337 patients, age averaged 7026 (5SD) years (range, 60 to 100). Body mass index was 26.153.3 kg/m2 in men and 26.554.0 kg/m2 in women. SBP at the clinic averaged 175k 12 mm Hg (range, 160 to 217) and DBP 8656 mm Hg (range, 49 to 94). The corresponding 24-hour pressures were 1485 16 mm Hg (range, 1 10 to 202) and 8059 lnln Hg (range, 58 to 138), respectively. Daytime versus awake and nighttime versus sleeping SBP and DBP did no1 differ Reproducibility of Clinic and Ambulatory Pressures at Baseline In 118 patients, ambulatory monitoring had been repeated during the run-in phase of the trial at a median interval of 33 days (range, 7 to 127). Reproducibility of the clinic pressure was studied by contrasting the averages of the two readings obtained with patients in the sitting position at two outpatient visits. Group means of the clinic and ambulatory pressures could be reproduced without significant changes in their values, except for the 24-hour, daytime, and awake SBP, which decreased (1-'<.05) by approximately 2 mm Hg, and for the awake DBP, which decreased (Pc.05) by 1 mm Hg Treatment Effects on Clinic and Ambulatory Pressures Follow-up averaged 13 months (median) (range, 4 to 30). Of the 337 paticnts, 310 remained on the lirst-line medication, ie, nitrendipine (n=151; daily dose, 27212 mg) or matching placebo (n=159). At the follow-up visit. second-and third-line medications had been started in 49 (1427 mg) and 21 (2226 mg) patients on active treatment and in 84 and 47 patients on placebo. Active treatment decreased the clinic and ambulatory SBP and DBP, but also during placebo these pressures tended to decline Over the follow-up period, no significant changes occurred in the patients' body weight (mean change?SD, -0.123.4 kg), smoking habits (-0.625.3 g tobacco per day), alcohol intake (-0.625.3 gld), serum y-glutamyltranspeptidase activity ([email protected]%), and score for the activities of daily living (median change, 0; range, -5 to +I). Modifications over the follow-up period in these lifestyle measures and previous antihypertensive treatment were not correlated with the decrease in the ambulatory BP values in the placebo group. The changes in body weight constituted the only possible exception because they tended to be positively associated with the changes in the 24-hour DBP (regression coefficientkSE, 0.2920.16 mm tiglkg; P=.07) and in the daytime (0.3820.20 mm Hgl kg, P=.OS) and nighttime (0.3520.19 mm Hglkg, P=.07) DBPs. Treatment Effects on Diurnal BP Profiles At both baseline and follow-up, time of day was a significant (P<.001) source of BP variation. At baseline, treatment allocation (!'=.g6 for SBP, P=.39 for DBP) as well as the interaction terms between treatment and time of day were not significant (P=.75 and .40, respectively). These results confirmed that during the run-in phase, the diurnal BP profiles were superimposable in the two treatment arms of the trial At follow-up, active treatment shifted (P<.001) the diurnal BP profile downward Disparity Between Clinic and Ambulatory Measurements At baseline, the correlation coefficients between the clinic and daytime measurements were .46 for SBP and .39 for DBP. The corresponding correlation coefficients at fc>llow-up were .57 and .49 in the placebo group and .32 and .35 during active treatment (PC.001 for all correlations). Clinic SBP was on all occasions higher (P<.001) than daytime SBP, ie, 21215 mm Hg at baseline, 14k17 mm Hg during placebo at follow-up, and 9&19 mm Hg during active treatment. In contrast, the mean differences between the clinic and daytime DBPs were small, averaging l + 10 mm Hg at baseline as well as during placebo at follow-up and -2+ 11 mm Hg during active treatment. 1)iscussion After approximately 1 year, the net separation in the clinic pressure between the two treatment groups aver- Approximately one third of the patients enrolled in the SYST-EUR Trial undergo ambulatory monitoring, in addition to conventional sphygmomanometry. The net separation between the two treatment arms after a median follow-up of approximately 1 year was considerably smaller for the ambulatory than for the clinic pressures, ie, 4.912.0 mm Hg less for the 24-hour pressures and 6.112.2 mm Hg less for the daytime pressures. Thus, the differentiation in the clinic pressures between the two treatment groups was 55%/59% larger than observed for the 24-hour pressures and 90%/69% larger than for the daytime pressures. The currently prevails that ambulatory recordings more closely reflect a patient's habitual BP level than the few readings taken by an auscultating observer in the stressful hospital e n v i r~n m e n t .~~-~T h e present study therefore suggests that the true BP responses in a long-term randomized clinical trial are overestimated by conventional sphygmomanometry by as much as 50% to 90%. The latter estimate is in agreement with a large meta-analysis of prospective observational studies in the field of hypertension.24 A correction for regression dilution bias was calculated by introducing the so-called usual BP, defined as an individual's average BP over several years. According to these ~alculations,2~ a 12 mm Hg difference in the baseline pressure was rescaled into a 7.5 mm Hg contrast in the usual pressure. Thus, BP measurements at a single occasion (baseline) were felt to inflate the gradient in the usual pressure by approximately 60%. Staessen et a1 Ambulatoly BP Monitoring During Placebo 417 BP measurements by conventional sphygmomanometry have guided patient recruitment and therapy in most clinical trials in the field of hypertension, including all outcome trials.2Wespite their track record, conventional BP readings are subject to the so-called placebo effect, often attributed to a gradual weakening of the alerting reaction22,23 and to a regression-to-the-mean phenomenon.2"-29 If conventional and anlbulatory measurements are repeated within the same subjects, the latter are characterized by greater reprodu~ibility,2~~ attributable to the absence-of digit preferen~e,"~ ob- server bias,") and the white coat reaction22,2'.31 but foremost to the greater number of readings averaged for calculation of the ambulatorv v a l~e s . 3~ This was confirmed in the present study, in which the clinic pressures dui-ing the placebo run-in period showed higher repeatahilily cc~cficicnts, signirying lowcr intrainclividual reproducibility, than the 24-hour and daytime pressures. Debate continues over whether ambulatory BP measurements decrease during placebo. The intra-arterially measured an~bulatory pressure has been demonstrated to remain at the same level when hypertensive patients were put on a placebo for 6 weeks."klong simiiar lines, in a 6-week study with a noninvasive recording technique,'4 the ambulatory pressure fell only slightly during the initial recording hours, such that the average BP over 24 hours stayed unaffected. On balance, most publications currently favor the view that the ambulatory pressure is not subject to a placebo e f f e~t . ' " ' "~~-~~. -7 " -~~ HOWever, few long-term studies on this subject have been published. A previous SYST-EUR publication4 based on 112 patients and limited to the placebo arm of the trial showed that after a median follow-up of 1 year the clinic SUP fell by 6.6 mm tIg (P<.001) and the 24-hour and daytime SBPs by 2.4 (P<.05) and 2.6 mm Hg (P=.06), respectively. The corresponding decreases in DBP were smaller, averaging only 1.4 (P-.06), 1.1, and 0.7 mm Hg.4 These estimates were of the same order of magnitude as in the present analysis, in which, because of the larger number of patients, the changes during placebo in the clinic and 24-hour DBPs also reached a level of statistical significance. The decline in the ambulatory BP values, amounting to approximately 2 mm Hg, may seem trivial and negligible. However, in relative terms they represented 43%1 23%, 20%/24%, and 30%/23% of the corresponding reductions in the clinic, 24-hour, and daytime SBPs/DBPs during active treatment. As far as the clinic pressure is vations, eg, during placebo, cannot be refuted and is part of the established culture among trialists. If this rule is true for the clinic pressure, then in opposition to the prevailing view in the literat~re,~3.1"2"-29,"3-4"t also needs to be applied for the ambulatory pressure, of which a substantial fraction may be explained by placebo-like effects. This reasoning not only involves the average 24-hour and daytime pressures but also the hourly BP means, which represent the treatment effects through the whole day. In the present study, the decreases in the hourly BP values during placebo constituted up to 70% of what was observed during active treatment. In the present study, the reduction in the clinic SBP during placebo may have been influenced by the 160 mm Hg threshold used to select the patients and by a subsequent regression-to-the-mean phenomenon. However, other mechanisms are also likely to have been at play because decreases during placebo were observed in the clinic DBP, which in all patients was lower than 95 mm Hg, as well as in the ambulatory measurements, which were not used to select the patients. Familiarization with the hospital environment or the procedure of ambulatory monitoring could be examples of such mechanisms. In addition, the present analysis demonstrated that changes in lifestyle were unlikely to be involved to a major extent. The clinic SBP was 21 mm Hg higher than the daytime pressure at baseline but only 14 and 9 mm Hg higher at follow-up during placebo and active treatment, respectively. These findings suggest that the white coat effect wears off as time goes by. It may also be attenuated by antihypertensive treatment, which probably dampens the BP surges caused by sympathetic arousal to the Staesserz et a1 Ambulatory BP Monitoring During Placebo 419 observer measuring the BP. Furthermore, the decreases in the ambulatory measurements during placebo and active treatlncnt were proportional to the BP level a1 baseline. T h e regression equations derived in the present studv vredicted that the 24-hour SBP would decrease , . by only 3.0 mm H g during active treatment in patients whose 24-hour SBP at entry was 135 mm Hg, ie, the 95th percentile in normotensive s~b j e c t s .~~h~s , in agreement with a previous report,47 prescribing antihypertensive medications to patients with a high clinic but low ambulatory pressure would not result in a substantial reduction of the habitual BP through the day. T h e issue of whether ambulatory measurements need to be corrected for placebo is not without importance, as it inherently touches o n the design of clinical trials in the field of hypertension. Some experts4x feel that ambulatory monitoring eliminates only observer bias and expectation4" and does not remove regression-to-the-mean and patient-related factors that contribute to the placebo effect. Other researchers defend the point of view that ambulatory monitoring would make control observations during placebo s u p e r f l~o u s .~~ If this were true, trials making use of the new technique could investigate antihypertensive interventions just by comparing the B P levels before and after therapy. T h e present findings suggest that the latter approach may lead t o a n overestimation of the true antihypertensive effect and should therefore be abandoned at least in long-term trials. A correction for placebo may even be warranted in shortterm trials because the reproducibility data in this study showed that after a median interval of 1 month the average 24-hour and daytime SBPs decreased during placebo by 1.8 and 2.4 mm Hg, respectively. Thus, clinical trials relying on ambulatory monitoring should adhere t o the same design standards as those making use of conventional sphygmomanometry. Despite theselimitations, ambulatory monitoring, compared with conventional B P readings, offers the advantage of providing information o n B P control through the whole day and makes it possible t o economize o n sample size in crossover but not parallel group trials.&quot

Are coronary event rates declining slower in women than in men – evidence from two population-based myocardial infarction registers in Finland?

<p>Abstract</p> <p>Background</p> <p>Studies have suggested that the prevention and treatment of coronary heart disease may not have been as effective in women as in men. Therefore, we aimed to examine whether the incidence, attack rate and mortality of myocardial infarction (MI) events have declined less in women than in men.</p> <p>Methods</p> <p>Two large population-based MI registers, the FINAMI register and the Finnish Cardiovascular Disease Register (CVDR) were used for comparing the event rates among men and women aged ≥35 years in two time periods, 1994–1996 and 2000–2002.</p> <p>Results</p> <p>In the FINAMI register a total of 5,252 events were recorded in men and 4,898 in women. Corresponding numbers in the CVDR were 78,709 and 70,464. Both FINAMI and CVDR data suggested smaller declines in incidence and attack rate of MI events in women than in men. In CVDR data the decline in mortality was also smaller in women than in men, while in FINAMI data this difference did not reach statistical significance. In the large CVDR data set, negative binomial regression models revealed smaller declines in incidence (p = 0.006), attack rate (p = 0.008) and mortality (p = 0.04) in women than in men aged <55 years. In persons ≥55 years no difference was observed between women and men.</p> <p>Conclusion</p> <p>The incidence and attack rate of MI events have declined less in women aged <55 than in men of similar age. In older persons no significant differences were observed. Further studies are warranted to find out the reasons why the development has been less favourable for young women than for men.</p

Mechanical properties of pulsed electric current sintered CrFeNiMn equiatomic alloy

Funding Information: Authors would like to thank Outokumpu Oyj for providing the raw materials used in this work as well as Prof. Uhlenwinkels group in Bremen University, Department of Production Engineering for carrying out the gas atomization of the powder. JL would like to thank Metallinjalostajat ry and Walter Ahlstr?m foundation for funding the research. This work made use of Aalto University RawMatters Facilities. Funding Information: Authors would like to thank Outokumpu Oyj for providing the raw materials used in this work as well as Prof. Uhlenwinkels group in Bremen University, Department of Production Engineering for carrying out the gas atomization of the powder. JL would like to thank Metallinjalostajat ry and Walter Ahlström foundation for funding the research. This work made use of Aalto University RawMatters Facilities. Publisher Copyright: © 2022 The AuthorsAn equiatomic CrFeNiMn alloy was consolidated using pulsed electric current sintering (PECS) from gas atomized (GA) powder. A range of sintering temperatures was applied to determine its impact on the received microstructure and material properties. It was found that the phase structure of the disc shape sintered samples varied greatly depending on the sintering temperature. According to X-ray diffraction (XRD) the surface of the samples contained a noticeable amount of BCC phase while in the middle of the sample cross sections no BCC phase was found. Ball milling of the gas atomized powder prior to sintering for 25 h increased the density and hardness of the sintered sample from 98.3% to 99% and from 200 HV to 300 HV, respectively. At the same time, the ultimate tensile strength increased from 700 MPa to 1000 MPa and the elongation at fracture decreased from 40% to 25%. The enhanced hardness and tensile strength were attributed to the grain refinement caused by milling the powder prior to sintering. Milling of the powder resulted in a reduction in grain size of the sintered material from 5.7 μm to 1.9 μm when sintered at 1100 °C for 5 min. The grain refinement was also found to affect the deformation mechanisms. While the deformation of the samples prepared directly from GA powder was accommodated by the cell-forming process and deformation twinning, milling refined the initial microstructure to such an extent that deformation twinning was suppressed. In summary, a single phase equiatomic CrFeNiMn alloy can be achieved by pulsed electric current sintering of gas atomized powder. Sintering at temperatures above 1100 °C results in a single-phase FCC structure excluding the surface of the samples. Milling of the starting powder increases the density and strength and decreases the grain size of the sintered material. Decrease in grain size also suppresses deformation twinning and promotes dislocation cell formation. As the CrFeNiMn alloy system does not contain cobalt as an alloying element it shows great promise tobe used in nuclear applications. The CrFeNiMn alloy showed good phase stability during tensile testing by not undergoing phase transformation contrary to metastable austenitic stainless steel where martensite transformations take place.Peer reviewe

Cold gas spraying of a high-entropy CrFeNiMn equiatomic alloy

Cold gas spraying was used to make a coating from an equiatomic CrFeNiMn high-entropy alloy. This four-component alloy was chosen because it is Co-free, thus allowing application in nuclear industries as a possible replacement of currently used stainless steel coatings. The feedstock material was gas atomized powder with a particle size distribution from 20 to 45 μm. A number of parameters were tested, such as the powder feed rate and gas feed pressure, in order to obtain as dense a coating as possible with nitrogen as the process gas. Spraying was performed using a gas preheating temperature of 1000 °C, gas feed pressure ranging from 50 to 60 bar, and two powder feeding rates. The coating thicknesses ranging from 230 to 490 m and porosities ranging from 3% to 10% were obtained depending on the powder feed rate and gas feed pressure. The hardness of the cross-section of the coating was usually lower than that of the surface. The highest coating hardness obtained was above 300 HV0.3 for both the surface and the cross-section. The as-atomized powder consisted of a face-centered cubic (FCC) phase with a minute amount of body-centered cubic (BCC) phase, which was no longer detectable in the coatings. The microstructure of the coating was highly stressed due to the high degree of deformation occurring in cold gas spraying. The deformation leads to strain hardening and induces a pronounced texture in the coating. The 111 planes tend to align along the coating surface, with deformation and texturing concentrating mainly on particle boundaries. A high-entropy alloy (HEA) coating was successfully sprayed for the first time using nitrogen as a process gas. The coating has the potential to replace stainless steel coatings in nuclear industry applications.Peer reviewe

Nanocellulose and Nanochitin Cryogels Improve the Efficiency of Dye Solar Cells

Biobased cryogel membranes were applied as electrolyte holders in dye solar cells (DSC) while facilitating carrier transport during operation. They also improved device performance and stability. For this purpose, cellulose nanofibers (CNF), TEMPO-oxidized CNF (TOCNF), bacterial cellulose (BC), and chitin nanofibers (ChNF) were investigated. The proposed materials and protocols for incorporating the electrolyte, via simple casting, avoided the typical problems associated with injection of the electrolyte through filling holes, a major difficulty especially in manufacturing large area cells. Owing to the fact that cryogel membranes did not require any orifice for injection, they were effective in minimizing leakage and in retaining liquid electrolyte. The results indicated the reduction of performance losses compared to conventional electrolyte filling, likely due to the better spatial distribution of electrolyte. DSCs based on BC cryogels had an initially higher performance and similar stability compared to those of the reference cells. When compared to reference cells, CNF and ChNF cryogels produced higher initial performance, but they underwent a faster degradation. The difference in stability was attributed to the effect of residual components, including lignin in CNF and proteins in ChNF, as demonstrated in bleaching experiments. TOCNF indicated a relatively poor performance, most likely because of residual aldehydes. Overall, we offer a comprehensive evaluation based on current-voltage (IV) profiles under simulated sunlight, incident photon-to-charge carrier efficiency (IPCE), electrochemical impedance spectroscopy (EIS), and color image processing, together with accelerated DSC stability tests, to unveil the effects of new membrane-based assembly. Our results give guidelines for future developments related in particular to the effects of the tested biomaterials on device stability.Peer reviewe